TrialCancer medicine2025

Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial.

Wenfeng Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.